Previous close | 1.9040 |
Open | 0.0000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0000 - 0.0000 |
52-week range | |
Volume | |
Avg. volume | 5,479 |
Market cap | 770,349 |
Beta (5Y monthly) | 1.05 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.3040 |
Earnings date | 30 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
PRESS RELEASE AB SCIENCE ANNOUNCES A SLIGHT DELAY IN THE PUBLICATION OF ITS 2023 ANNUAL FINANCIAL REPORT THE COMPANY WILL PUBLISH ITS 2023 ANNUAL FINANCIAL REPORT NO LATER THAN 15 MAY 2024 Paris, April 30 2024, 6.30pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2023 annual financial report, initially scheduled for 30 April 2024, to give the auditors time to complete their audit work. The Company will publish its 2023 annual financ
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS GRANTED ELIGIBILITY FOR RECONSIDERATION REQUEST FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS Paris, 3 April, 2024, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that Health Canada has granted eligibility for reconsideration request for masitinib in amyotrophic lateral sclerosis (ALS). The reconsideration process will re-examine, with new assessors, the decision based on information that was included in the origina
PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM NEUROFILAMENT LIGHT CHAIN, AN IMPORTANT BIOMARKER FOR NEURODEGENERATIVE DISORDERS Paris, March 13, 2024, 12.45pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced the publication of new preclinical results for masitinib in neurodegenerative diseases (NDD). Findings have been published on the